Aclaris Therapeutics (ACRS) Given Daily News Sentiment Rating of 0.19

Media stories about Aclaris Therapeutics (NASDAQ:ACRS) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aclaris Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.2426279949165 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news articles that may have effected Accern Sentiment’s scoring:

Aclaris Therapeutics stock traded up $0.13 during midday trading on Friday, reaching $17.73. The stock had a trading volume of 267,875 shares, compared to its average volume of 232,267. Aclaris Therapeutics has a 1-year low of $16.01 and a 1-year high of $32.33. The firm has a market cap of $547.87, a PE ratio of -7.09 and a beta of 1.63.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.10. The firm had revenue of $1.00 million during the quarter, compared to analyst estimates of $0.80 million. analysts anticipate that Aclaris Therapeutics will post -4.27 EPS for the current fiscal year.

A number of equities research analysts have recently commented on ACRS shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $50.00 price target on shares of Aclaris Therapeutics in a research report on Monday, March 12th. BidaskClub lowered Aclaris Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Zacks Investment Research raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 19th. Leerink Swann dropped their target price on Aclaris Therapeutics from $54.00 to $52.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 28th. Finally, Guggenheim initiated coverage on Aclaris Therapeutics in a research report on Thursday, February 8th. They issued a “buy” rating and a $53.00 target price on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $43.50.

In related news, insider Neal Walker purchased 10,000 shares of the firm’s stock in a transaction on Thursday, April 5th. The stock was purchased at an average cost of $16.75 per share, for a total transaction of $167,500.00. Following the completion of the purchase, the insider now directly owns 897,184 shares in the company, valued at $15,027,832. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Stephen A. Tullman purchased 26,700 shares of the firm’s stock in a transaction on Friday, April 6th. The stock was bought at an average price of $16.54 per share, with a total value of $441,618.00. Following the completion of the purchase, the director now owns 157,507 shares of the company’s stock, valued at $2,605,165.78. The disclosure for this purchase can be found here. In the last three months, insiders purchased 37,950 shares of company stock worth $629,856. 16.30% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: “Aclaris Therapeutics (ACRS) Given Daily News Sentiment Rating of 0.19” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Insider Buying and Selling by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit